There is downside revision risk to the 2026 consensus EBITDA estimates for Hims & Hers Health Inc HIMS, with the EBITDA ...

Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on the stock to $25 from $21 while maintaining a Neutral rating. The catalyst: the FDA took a ...

) has been revised to $25.63 / share. This is a decrease of 14.58% from the prior estimate of $30.00 dated February 21, 2026. The price target is an average of many targets provided by analysts. The ...

Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression ...

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 10 Fastest Growing NYSE Stocks to Buy. On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48 ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers (HIMS) stock fell 39% in 2026 after shifting to branded GLP-1 drugs. Amazon's Foundayo launch adds pressure.

Hims & Hers Health (NYSE:HIMS), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as ...

Hims & Hers Health, Inc. (NYSE:HIMS) ranks among the most shorted stocks to buy according to analysts. Following Novo Nordisk’s lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS), Canaccord Genuity ...

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the ...

Hims & Hers also said it is shifting its U.S. weight-loss business away from actively advertising compounded GLP-1 drugs and toward a wider assortment of FDA-approved treatments. Existing patients may ...